Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Mental health care before cancer treatment is associated with higher death rates for those with kidney, prostate or bladder cancer.
In two large clinical trials, an immune checkpoint inhibitor combined with a targeted therapy had better outcomes than the standard of care.
Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.
Incidence is increasing for six of 12 obesity-related cancers, including colorectal, kidney and pancreatic.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.